Overexpression of Thrombomodulin in Adipose-Derived Mesenchymal Stem Cells Reduces Thrombogenic Risk and Enhances Therapeutic Efficacy.
Tanaka Y., Nakashima A., Ishiuchi N., Miyasako K., Morimoto K., Yoshida M.
Animal Study on Chronic Kidney Disease, published in J Am Soc Nephrol (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Am Soc Nephrol (2026)
- Country
- United States
- Reported sample size
- —
- PMID
- 40711826
- DOI
- 10.1681/ASN.0000000810
Abstract (original English)
Thrombomodulin on the cell surface acts as an anticoagulant and antifibrinolytic factor by binding to thrombin. Enhancement of thrombomodulin expression reduced renal infarction and pulmonary embolism induced by adipose-derived mesenchymal stem cells. Adipose-derived mesenchymal stem cells with enhanced thrombomodulin potentiated anti-inflammation and antifibrotic effects. Adipose-derived mesenchymal stem cells (ASCs) are expected to be a new therapy for organ injury; however, they were reported to have procoagulant activity, raising concerns about thrombogenic risk. Thrombomodulin acts as an anticoagulant factor by binding to thrombin, leading to the hypothesis that ASCs overexpressing thrombomodulin (TM-ASCs) could be safely used for cell therapy by reducing the risk of thromboembolism. TM-ASCs were generated using adeno-associated virus carrying thrombomodulin cDNA. To examine the risk of ASC-induced renal infarction, ASCs were administered through renal artery into rats with unilateral ischemia-reperfusion injury (IRI) and contralateral nephrectomy. To assess the risk of ASC-induced pulmonary embolism, ASCs were injected into rats through tail vein. In addition, we examined whether TM-ASCs potently inhibited inflammatory cell infiltration and kidney fibrosis in IRI rats. Furthermore, we explored synthetic compounds that enhanced thrombomodulin expression in ASCs. Overexpres
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence comes from animal or laboratory studies and has not been confirmed in humans.
How we grade evidenceRelated research
- Level ASystematic Review
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci - Level AMeta-analysis
A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease.
Meta-analysis on Chronic Kidney Disease, published in Stem Cells Transl Med (2021) — summary generated from the PubMed abstract.
- 2021
Stem Cells Transl Med - Level BRandomized Controlled Trial
Clinical efficacy and safety of allogeneic adipose-derived stem cells ELIXCYTE in chronic kidney disease: a phase I/II study.
Randomized Controlled Trial on Chronic Kidney Disease, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cells Transl Med - Level BRandomized Controlled Trial
Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas.
Randomized Controlled Trial on Chronic Kidney Disease, Chronic Inflammation, Autoimmune Research, published in Sci Transl Med (2025) — summary generated from the PubMed abstract.
- 2025
Sci Transl Med - Level BClinical Trial
Safety of Stromal Vascular Fraction Cell Therapy for Chronic Kidney Disease of Unknown Cause (Mesoamerican Nephropathy).
Clinical Trial with a reported sample of 18 on Chronic Kidney Disease, published in Stem Cells Transl Med (2023) — summary generated from the PubMed abstract.
- 2023
- n = 18
Stem Cells Transl Med - Level BClinical Trial
Allogeneic adipose tissue-derived stem cells ELIXCYTE ® in chronic kidney disease: A phase I study assessing safety and clinical feasibility.
Clinical Trial with a reported sample of 12 on Chronic Kidney Disease, published in J Cell Mol Med (2022) — summary generated from the PubMed abstract.
- 2022
- n = 12
J Cell Mol Med